Aims: The association of the endothelial dysfunction(ED) marker - Plasminogen Activator Inhibitor-1(PAI-1), insulin resistance(IR) indicators and the cardiovascular risk(CVR) to study in patients with prediabetes and without cardiovascular event(CVE).
Materials and methods. A case-control study conducted, including 406 people, aged 18 to 65 years. The glycated hemoglobin(HbA1c,%), C-peptide, insulin, biomarker PAI-1, IR index HOMA measured. After clinical examination, patients were divided into 3 groups: 1 – the control group n=20, 2 group – the prediabetes without CVE n=80, 3 group - the prediabetes with CVE n=30.
Results. Significant differences the PAI-1 level were found between the 2 group(PAI-1; Me -29754,3 pg/ml) and the 3 group(Me-36867,2 pg/ml) in comparison with the control group(Me-24238,5 pg/ml; p=0,000).We considered Means±SD the PAI-1 level based on SCORE scale in the 2 group: PAI-1in the low CVR group SCORE(<1points) was 32345,1±24191,7 pg/ml; in the high CVR group SCORE(>1points) Mean was-38570,7±22768,7 pg/ml;p=0,000. The relationship between PAI1 and SCORE points found(r=0,23; р=0,001).The relationship PAI-1 with glucagon(r=0,23; р=0,001), HOMA index(r=0,27; р=0,000), С-peptide(r=0,25; р=0,001), fasting glucose(r=0,23; р=0,000) found. The relationship SCORE points with insulin(r=0,43; р=0,001), HOMA index(r=0,47; р=0,000), С-peptide(r=0,38; р=0,001), LDL(r=0,4; р=0,000), triglycerides(r=0,32; р=0,000) determined. On increasing PAI-1 biomarker level affected elevation SCORE points on 2,6 fold(р=0,05), HbA1c on 1,3 fold(р=0,05), hyperglucemia on 1,2 fold(р=0,02) based on results polynomial regression.
Conclusions. We found the association of the PAI-1 biomarker, IR indicators and the CVR in patients with prediabetes. Indicating that with an increase of the PAI-1, IR increases and thereby increases the CVR and ED in these patients.